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ABSTRACT
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of 
rare high grade neuroendocrine tumors that often behave clinically like small cell 
carcinoma (SCLC) and are treated as such. No major advancement in the management 
of these tumors has occurred in the last 30 years. 
Methods: We present a case series of three cases from Markey Cancer center 
along with a review of 13 published cases in the literature wherein immune-checkpoint 
inhibitors were utilized in the management of LCNEC. 
Results: Immune-checkpoint inhibitors might have clinical activity in LCNEC. 
Conclusion: Role of immune-checkpoint inhibitors should be explored in 
prospective LCNEC clinical trials. We summarize current evidence regarding use of 
immune checkpoint inhibitors in the treatment of LCNEC.
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INTRODUCTION 
Large cell neuroendocrine carcinomas (LCNEC) 
are a group of rare high grade neuroendocrine tumors that 
often behave clinically like small cell carcinoma (SCLC) 
and are treated as such. These tumors can arise anywhere 
in the body, but pulmonary LCNEC is by far the most 
common. Patients usually present with extensive disease 
and have a poor prognosis. Platinum-based chemotherapy 
is often the treatment of choice, similar to SCLC, but 
response is short-lived. No standard second line treatment 
exists. Various combinations of taxane- or irinotecan-
based chemotherapies have yielded poor response 
rates. Clinical trials are few and are difficult to conduct 
due to rarity of the disease. No major advancement in 
management of these tumors has occurred in the last 30 
years. We summarize current evidence regarding immune 
checkpoint inhibitors in the treatment of LCNEC.
RESULTS
To our knowledge, there are only two published case 
reports and one poster presentation that retrospectively 
reviewed the efficacy of immune checkpoint inhibitors in 
LCNEC. We would like to add our single center clinical 
experience with immune checkpoint inhibitors (n = 3) and 
also summarize the existing published clinical data to date. 
Levra et al. presented their data on use of 
immune checkpoint inhibitors in pulmonary LCNEC 
at the IASLC 18th World Conference on Lung Cancer 
in 2017. Ten patients were treated with immune 
checkpoint inhibitors (9 with nivolumab and 1 with 
pembrolizumab). Six of the ten showed a partial 
response and one demonstrated stable disease. Median 
progression free survival was reported as 57 weeks and 
the median number of doses of immune checkpoint 
inhibitor therapy received was 16 [1].
Daido et al. reported 2 cases of LCNEC who 
received nivolumab as third and sixth line of salvage 
therapy for progressive metastatic disease. The authors 
reported a radiological response to immune checkpoint 
inhibitor therapy but the degree and duration of response 
was not presented [2].
Wang et al. reported a single case of pulmonary 
LCNEC in 2017 with an exceptional response to a first 
dose of pembrolizumab. The patient was continuing 
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treatment at the time of publication of the case study so the 
duration of response cannot be determined [3].
Table 1 describes 3 cases of LCNEC managed at the 
University of Kentucky with ongoing durable response to 
immune checkpoint inhibitor therapy.
DISCUSSION
In 2016, Rekhtman et al. described genomic 
alterations sequenced in pulmonary LCNEC and, 
interestingly, LCNEC patients can be subdivided into 
SCLC and non-SCLC (NSCLC) cohorts based on the 
genetic signatures of their tumor [6]. This finding implies 
that treating all LCNEC patients with SCLC regimens 
might be suboptimal. Immune checkpoint inhibition is 
a gratifying treatment option especially for NSCLC and 
could be explored for LCNEC. About 60% of pulmonary 
LCNEC do not exhibit the small cell hallmark signature 
(TP53 and Rb1 co-mutation) which might explain the 
large percentage of LCNEC patients who are platinum-
refractory or rapidly progress on a platinum doublet. 
Prospective data regarding use of immune checkpoint in 
LCNEC is lacking but small pre-clinical data sets support 
further exploration of immune checkpoint in LCNEC.
Fan et al. studied PDL and PD-L1 expression 
in pulmonary neuroendocrine tumors. Ten out of 80 
patients in their cohort were LCNEC. All 10 LCNEC 
were positive for PD-L1 and 8 out of 10 were positive 
for PD-1 [4]. More recently, Tsuruoka et al. analyzed 
PD-L1 expression in 227 pulmonary neuroendocrine 
tumors, 106 of which were LCNEC. Unlike the previous 
study, PD-L1 expression was modest (10.4%). Karim 
et al, recently reported PD-L1 tumoral expression in 5/24 
(21%) cases albeit 2 cases with only 1% staining in 1 out 
of the 3 cores from each patient on the tissue microarray 
[7]. The variability in percentages noted in these studies 
may be explained by the relatively small sample numbers 
of LCNEC cases employed. However, in comparison to 
SCLC and low grade neuroendocrine tumors where 5.8% 
and 0% of the cases respectively were PDL-1 positive, 
LCNEC still exhibit a higher positivity among all 
pulmonary neuroendocrine tumors [5].
Although the correlation of PD-1 and PD-L1 
expression with response to immune checkpoint inhibitor 
therapy remains under investigation, the presence of PD-1/
PD-L1 in LCNEC is interesting, especially considering 
the scarcity of treatment options and potential therapeutic 
targets in this rare and very aggressive malignancy.
Clinical trials in rare tumors are difficult to conduct, 
hence strong prospective data regarding management of 
LCNEC is lacking. No prospective data regarding the use 
of immune checkpoint inhibitor is currently available, but 
is warranted. 
Table 1: LCNEC patients treated with immune checkpoint inhibitors at Markey Cancer Center, University of Kentucky
Patient Prior treatment Current treatment Response
80 Y/O F with metastatic gastric 
LCNEC
6 cycles of cisplatin and 
etoposide. 
Disease progression in liver 
three months after platinum 
doublet completion. 
Second line, off label 
nivolumab q 2 weeks 
for past 6 months 
and continuing. 




57 Y/O with metastatic LCNEC of 
lung with brain metastasis 
Resection of brain metastasis 
followed by radiation, 
carboplatin and etoposide X 4 
cycles, intolerance to further 
platinum doublet. 
Switched to maintenance 
pemetrexed X 21 cycles, 
developed toxicity to 
pemetrexed.
Switched to off label nivolumab.
Nivolumab 
discontinued post 
4 doses due to 





Off therapy for 15 
months now. 
39 Y/O F with metastatic LCNEC 
of lung. 
Positive for following mutations; 
STK11, AURKA, AXL, MYC, 
CCNE1, GNAS, KEAP1, MCL1, 
RUNX1, TP53.
High tumor mutation burden and 
PD-L1 positive.  
Carboplatin and etoposide X 
5 cycles. Radiological disease 
progression. 
Switched to nivolumab based 
on molecular tumor board 
recommendation. 
Currently on 
nivolumab q 2 weeks
Status post 15 doses
Radiological and 
clinically stable disease. 
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